About Us

BIAL Biotech is a center of excellence for the development of genetically-defined Parkinson’s disease therapeutics located in the heart of the Boston biotech cluster. BIAL Biotech is a wholly owned subsidiary of BIAL.

We are dedicated to innovative, research and development in the field of neurodegeneration.

Our lead program builds on the genetic association between Parkinson’s disease (PD) and the GBA1 gene. BIAL Biotech team has extensive experience in drug discovery and development, focused on genetic and neurodegenerative diseases. Our team is highly motivated to make a real difference as soon as possible for patients with severe neurodegenerative and neurodevelopmental disease.

Management team

Kees Been


Kees Been was formerly the President and CEO of EnVivo Pharmaceuticals; He led EnVivo for eight years from an early-stage start-up to a respected CNS company with a broad pipeline of NCE drug compounds, its lead compound in a phase 3 program for Alzheimer’s disease and schizophrenia. He spent four years at Biogen where he directed the Oncology Business Unit which was sold to Idec, and, as Senior Vice President of Business Development.

Peter Lansbury, PhD

Chief Scientific Officer

Peter Lansbury manages the company’s research activities. He also retains his position as a professor of neurology at Harvard Medical School. Previously, Peter was Founder and Chief Scientific Officer of Link Medicine until it was acquired by AstraZeneca in 2012. Peter served as a Director of the Morris K. Udall Research Center of Excellence in Parkinson's Disease at Brigham and Women's Hospital. Peter received his doctorate from Harvard University, where he worked for Nobel laureate E. J. Corey.

David Simon, MD/PhD

Senior Advisor – Clinical Research

David K. Simon is a Senior Advisor for BIAL Biotech. He earned MD and PhD degrees from Washington University in St. Louis and completed the Harvard-Longwood Neurology Residency in Boston, followed by a Movement Disorders Fellowship at Massachusetts General Hospital. He is a Professor of Neurology at Harvard Medical School and Chief of the Division of Movement Disorders at Beth Israel Deaconess Medical Center (BIDMC). He has served as an investigator for 20 multicenter clinical studies in Parkinson’s disease, and on the Steering Committees for several clinical studies of potential neuroprotective strategies. He is a member of the Cure Parkinson’s Trust International Linked Clinical Trials Committee, Chairs the Scientific Advisory Board of the Weston Brain Institute, and served a term as an elected member of the Parkinson’s Study Group Executive Committee. He also conducts translational laboratory studies focusing on potential neuroprotective strategies in Parkinson’s disease.

Nikki Shannon

VP of Clinical Operations and Program Management

Nikki Shannon has more than 25 years of experience in clinical development operations and program management, and has held global senior level clinical development operations roles at a number of pharmaceutical companies, including Merck, AstraZeneca, Vertex & Tetraphase. Most recently, Nikki was Vice President, Clinical Operations at NeuroBo Pharmaceuticals. Of note, Nikki has held senior global clinical operational roles in 3 product submissions and approvals.

Nuno Mendonça, MD

Chief Medical Officer

Nuno Mendonça leads the company’s development activities. He is a board certified neurologist with experience in neurodegenerative and rare/orphan neurologic disorders. Nuno Mendonça joined industry after completing the Harvard Medical School Clinical Scholars Research program. He spent 6 years at AbbVie where he led the development of assets in Alzheimer’s and Parkinson’s disease across different stages of drug development. Nuno worked as a Senior Medical Director for 2 years at Novartis Gene Therapies, where he participated on the EMA approval of Zolgensma for spinal muscular atrophy.